Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699374 · ClinicalTrials.gov registry record · Phase 3
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,075
- Enrollment target
NCT00699374 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,075 participants.
The verdict
NCT00699374, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,075 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.
Interventions
- DRUG sorafenib
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,075 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00699374
The ClinicalTrials.gov registry entry for NCT00699374 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,075 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT00699374 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00699374 about?
NCT00699374 is a clinical study titled "Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer". The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Stud...
What is the current status of trial NCT00699374?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,075 participants. The study started on 2008-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00699374?
The interventions under investigation include: sorafenib (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00699374?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.